Abstracts tagged "Infection"

Abstract Number: 1317 • 2016 ACR/ARHP Annual Meeting
Do Patients with MRSA-Positive Septic Arthritis Differ Clinically from Non-MRSA-Positive Counterparts?
Mary Louise Fowler¹, Kevin Byrne¹, Sarah B. Lieber², Andy Moore³, Robert Shmerling⁴ and Ziv Paz², ¹Boston University School of Medicine, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Division of Rheumatology, Cambridge Health Alliance, Harvard Medical School, Boston, MA, ⁴Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA
Do patients with MRSA-positive septic arthritis differ clinically from non-MRSA-positive counterparts? Mary Louise Fowler3, Kevin Byrne3, Sarah B. Lieber1, Andrew Moore2, Robert H. Shmerling1, Ziv…
Abstract Number: 1351 • 2016 ACR/ARHP Annual Meeting
Mortality and Prognostic Factors of Pneumocystis Pneumonia in Patients with Connective Tissue Diseases
Mitsuhiro Akiyama¹, Yuko Kaneko² and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine,, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Pneumocystis pneumonia (PCP) is one of the severe opportunistic infections in immunocompromised patients. PCP is still a leading cause of death in patients with…
Abstract Number: 1502 • 2016 ACR/ARHP Annual Meeting
Vaccination Program to Prevent Hospital Admissions Due to Serious Respiratory Infections in Rheumatoid Arthritis Patients. Prosprective Study of 294 Patients
Lucia C. Domínguez-Casas¹, Paz Rodríguez-Cundín², Vanesa Calvo-Río¹, Ricardo Blanco¹, Nuria Vegas-Revenga³, Carlos Fernández Díaz¹, Virginia Portilla³, FM Antolin², MH Rebollo-Rodrigo², Alfonso Corrales¹, Natalia Palmou-Fontana¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Patients with Rheumatoid Arthritis (RA) are at increased risk of infections, especially serious respiratory infections. Immunization is a recommended to reduce these complications.…
Abstract Number: 1684 • 2016 ACR/ARHP Annual Meeting
Updated Results for Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Christopher T. Ritchlin¹, Alan Menter², Philip J Mease³, Sunil Kalia⁴, Francisco Kerdel⁵, Shelly Kafka⁶, James Morgan⁶, Wayne Langholff⁷, Steve Fakharzadeh⁶, Kavitha Goyal⁶ and Alice Gottlieb⁸, ¹Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Baylor Research Institute, Dallas, TX, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵University of Miami, Miami, FL, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Tufts University School of Medicine (affiliation at the time of the study), Boston, MA
Background/Purpose: To describe the rates of serious infections (SI) in psoriasis (PsO) pts with psoriatic arthritis (PsA) from PSOLAR, & assess risk with biologic therapy.…
Abstract Number: 1925 • 2016 ACR/ARHP Annual Meeting
Interest of Procalcitonin for the Follow-up of ANCA-Associated Vasculitis: Data from a Cohort of 99 Patients
Anne Lemaire¹, Roderau Outh¹, Alexandre Mania¹, Geoffroy Marceau², Pauline Berland³, Marc Andre⁴ and Olivier Aumaître⁵, ¹Internal Medicine CHU G Montpied, Internal Medicine, CLERMONT-FERRAND, France, ²Biology, Medical Biochemistry, CLERMONT-FERRAND, France, ³Epidemiology, Epidemiology, CLERMONT-FERRAND, France, ⁴Internal Medicine CHU G Montpied, Internal Medicine, Clermont Ferrand, France, ⁵Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France
Background/Purpose: The prognosis of the ANCA associated vasculitis (AAV) has improved with the new immunosuppressive treatments but infectious complications remain frequent. Procalcitonin (PCT) is…
Abstract Number: 403 • 2016 ACR/ARHP Annual Meeting
High Rate of Serious Infection in Juvenile Idiopathic Arthritis Under Biologic Therapy in a Real Life Setting
Juliana Brunelli¹, Ana Renata Schmidt¹, Adriana M E Sallum², Cláudia Goldenstein-Schainberg³, Eloisa Bonfa⁴, Clovis A Silva⁵ and Nadia E Aikawa⁶, ¹Pediatric Rheumatology, University of São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil, ³Rheumatology Division, University of São Paulo, São Paulo, Brazil, ⁴Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁶Pediatric Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Most data about infections associated to biologic therapy in juvenile idiopathic arthritis (JIA) derive from registries designed to identify general adverse events that have…
Abstract Number: 2049 • 2016 ACR/ARHP Annual Meeting
Serious Infections in RA Offspring Exposed to Tumor Necrosis Factor Inhibitors
Evelyne Vinet¹, Cristiano S. Moura², Jeffrey R. Curtis³, Christian A. Pineau⁴, Michal Abrahamowicz² and Sasha Bernatsky⁵, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Center for Education and Research on Therapeutics, University of Alabama at Birmingham, Birmingham, AL, ⁴McGill University Health Centre, Montreal, QC, Canada, ⁵Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are increasingly used during RA pregnancy. Most of these are actively transported across the placenta, reaching higher fetal than maternal…
Abstract Number: 523 • 2016 ACR/ARHP Annual Meeting
Mortality Profile of Patients with Rheumatoid Arthritis in France and Its Change in 10 Years
Jerome Avouac¹, Fazia Amrouche², Christophe Meune³, Grégoire Rey⁴, Andre Kahan⁵ and Yannick Allanore⁶, ¹Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ²Paris Descartes University, Cochin Hospital, Paris, France, ³Cardiology department, Université Paris XIII, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Bobigny, France, ⁴Inserm-CépiDc, Hospital Bicêtre, Le Kremlin-Bicêtre, France, ⁵Service de Rhumatologie A, Hopital Cochin, Paris Cedex 14, France, ⁶Rheumatology, Paris Descartes University, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with an excess of mortality. This risk depends on the disease activity, severity and associated comorbidities. Our objective was…
Abstract Number: 2079 • 2016 ACR/ARHP Annual Meeting
Incidence and Risk of Pneumocystis Jirovecii Pneumonia Following Rituximab Treatment in Granulomatosis with Polyangiitis in the United States: An Analysis from a National Database
Sirada Panupattanapong¹, Anthony R. French², Andrew J. White², Margaret A. Olsen³, Maya Rendulic⁴ and Mary E. Hartman⁵, ¹Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ²Division of Pediatric Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ³Division of Infectious Disease, Washington University School of Medicine, St. Louis, MO, ⁴Center for Administrative Data Research, Washington University School of Medicine, St. Louis, MO, ⁵Division of Pediatric Critical Care Medicine, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO
Background/Purpose: Pneumocystis Jirovecii pneumonia (PJP) is a life-threatening complication in granulomatosis with polyangiitis (GPA). Guidelines from EULAR for ANCA-associated vasculitis (AAV) recommend institution of PJP…
Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting
Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Theodora Bejan-Angoulvant¹, David Ternant², Fadela Daoued³, Frédéric Medina³, Louis Bernard⁴, Saloua Mammou³, Gilles Paintaud² and Denis Mulleman⁵, ¹Service de Pharmacologie Clinique, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ²Laboratoire de Pharmacologie-Toxicologie, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ³Service de Rhumatologie, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁴Service des Maladies Infectieuses, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁵Service de Rhumatologie, Rheumatology department, François-Rabelais University, CNRS 7292, CHRU de Tours, Tours, France
Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…
Abstract Number: 2310 • 2016 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Complication of Infection during the Treatment for Inflammatory Myopathies Complicated with Interstitial Lung Disease
Yumiko SUGIYAMA^1,2, Maasa Tamura^1,2,3, Ryusuke Yoshimi^1,2, Naoki Hamada^1,2, Hideto Nagai^1,2, Yuko Tatekabe^1,2, Naomi Tsuchida^2,4, Yutaro Soejima^1,2, Yosuke Kunishita^2,4, Daiga Kishimoto^1,2, Hiroto Nakano^1,2, Reikou Kamiyama^1,2, Kaoru Minegishi^2,5, Yukiko Asami^1,2, Yohei Kirino^2,4, Shigeru Ohno^2,5 and Hideaki Nakajima¹, ¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Y-CURD Study Group, Yokohama, Japan, ³Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁴Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, ⁵Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the predominant causes of death in polymyositis/dermatomyositis (PM/DM). We have already reported that low PaCO2 and interstitial…
Abstract Number: 773 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Severe Infections in Rituximab Treated Patients: Comparison of Systemic Lupus Erythematosus and Inflammatory Myositis
Cristiane Medeiros¹, Luciana Seguro², Fernando Henrique Carlos de Souza², Nadia E Aikawa³ and Eloisa Bonfa⁴, ¹Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil
Background/Purpose: The use of Rituximab (RTX) in patients with autoimmune diseases has been associated with an increased incidence of infection and risk factors for this…
Abstract Number: 2543 • 2016 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World
John Kelsall¹, Anna Jaroszynska², Louis Bessette³, Raman Joshi⁴, Isabelle Fortin⁵, Jacqueline Stewart⁶, Keltie Anderson⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Francois Nantel¹⁰, Karina Maslova¹¹, Brendan Osborne¹², Cathy Tkaczyk¹² and Allen J Lehman¹¹, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Private practice, Burlington, ON, Canada, ³Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁴William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ⁵Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, ⁶Penticton Regional Hospital, Penticton, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Methotrexate (MTX) is routinely used among rheumatoid arthritis (RA) patients treated with anti-TNF agents to enhance treatment efficacy and minimize the dose of biologic…
Abstract Number: 1000 • 2016 ACR/ARHP Annual Meeting
Subclinical Cytomegalovirus Viremia Is Associated with Increased Nosocomial Infections and Prolonged Hospitalization in Patients with Systemic Autoimmune Diseases
John McKinnon¹, Junying Zhou², Jenna Hudy¹, Sara Hegab¹ and Kathleen Maksimowicz-McKinnon³, ¹Henry Ford Hospital, Detroit, MI, ²Infectious Diseases, Henry Ford Hospital, Detroit, MI, ³Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: Both subclinical cytomegalovirus (CMV) viremia and CMV disease have been associated with adverse outcomes in select immunosuppressed populations, including an increased incidence of other…
Abstract Number: 2575 • 2016 ACR/ARHP Annual Meeting
The Presence of Staphylococcal Toxins in the Urine of Patients with Rheumatoid Arthritis
Laura Grace¹, Marwan Bukhari², Robert Lauder³, Lisa Bishop^4,5 and Adam Taylor¹, ¹Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ²Royal Lancaster Infirmary, Lancaster, United Kingdom, ³Biomedical & Life Sciences, Lancaster University, Lancaster, United Kingdom, ⁴Biomedical and Life Sciences, Lancaster University, Lancaster, United Kingdom, ⁵University Hopsitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a disease of unknown etiology;with a pathogenesis that is due to a mixture of genetic, immunological and environmental factors. A…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.